Data from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Minjee Kim(Massachusetts Eye and Ear Infirmary), Jann N. Sarkaria(Mayo Clinic), James Watters(Sanofi (France)), Karen E. Parrish(University of Minnesota), Rachael A. Vaubel(Mayo Clinic), William F. Elmquist(Pediatrics and Genetics), Jeanette E. Eckel‐Passow(Mayo Clinic in Florida), Ian F. Parney(Mayo Clinic), Aaron J. Johnson(Mayo Clinic), Nathalie Y.R. Agar(Texas Endosurgery Institute), Laurent Debüssche(Sanofi (France)), J. Daniel, David Calligaris(Texas Endosurgery Institute), Ryan W. Feathers(Mayo Clinic in Florida), Paul A. Decker(University of California, San Francisco), Fang Jin(China Medical University), Isabelle Meaux(Sanofi (France)), Ann C. Mladek(Mayo Clinic), Gaspar J. Kitange(University of California, San Francisco), Cédric Barrière(Sanofi (France)), Panos Z. Anastasiadis(Mayo Clinic in Florida), Shulan Tian(Mayo Clinic in Arizona), Shuangling Zhang(University of Minnesota)
Cited by 0
Related Papers
Rapid, Label-Free Detection of Brain Tumors with Stimulated Raman Scattering Microscopy
|Science Translational Medicine|2013|510
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
|Science Immunology|2022|366
SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
|Cancer Research|2014|337
Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors
|Proceedings of the National Academy of Sciences|2013|288